Sean A Fletcher1,2, Sabrina S Harmouch1,2, Marieke J Krimphove2,3, Alexander P Cole1,2, Sebastian Berg2,4, Philipp Gild2,5, Mark A Preston1, Guru P Sonpavde6, Adam S Kibel1, Maxine Sun6, Toni K Choueiri6, Quoc-Dien Trinh7,8. 1. Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St, ASB II-3, Boston, MA, USA. 2. Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 3. Department of Urology, University Hospital Frankfurt, Frankfurt Am Main, Germany. 4. Department of Urology and Neuro-Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. 5. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 6. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 7. Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St, ASB II-3, Boston, MA, USA. qtrinh@bwh.harvard.edu. 8. Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. qtrinh@bwh.harvard.edu.
Abstract
INTRODUCTION: Muscle-invasive bladder cancer (MIBC) is an aggressive disease for which treatment strategies are continuously evolving. We characterized trends in treatment modalities for MIBC from 2004 to 2013 (the "pre-immunotherapy era") and identified predictors of receiving the current standard of care treatment: neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). METHODS: We used the National Cancer Database to identify individuals diagnosed with clinically localized MIBC from 2004 to 2013. We calculated the yearly prevalence of NAC followed by RC, RC as first treatment, trimodal therapy, chemotherapy and/or radiation alone, and no treatment. We then identified factors associated with receiving NAC prior to RC. RESULTS: There was a notable increase in the use of NAC followed by RC over the study period, from 3.68% in 2004 to 14.83% in 2013 (P < 0.001). Factors associated with decreased odds of receiving this regimen included being older, Black, uninsured, less educated, and more burdened by comorbidities. Rates of trimodal therapy and chemotherapy and/or radiation alone remained relatively constant (approximately 5 and 17%, respectively). There was a consistent decline in the proportion of patients who did not receive any treatment, down to 34.20% in 2013. CONCLUSION: Trends in localized MIBC treatment have evolved substantially since the early 2000s, and certain patient characteristics are associated with lower odds of receiving the current standard of care. This serves as a foundation from which to judge the impact of the upcoming immunotherapy era on the treatment landscape for this disease.
INTRODUCTION:Muscle-invasive bladder cancer (MIBC) is an aggressive disease for which treatment strategies are continuously evolving. We characterized trends in treatment modalities for MIBC from 2004 to 2013 (the "pre-immunotherapy era") and identified predictors of receiving the current standard of care treatment: neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). METHODS: We used the National Cancer Database to identify individuals diagnosed with clinically localized MIBC from 2004 to 2013. We calculated the yearly prevalence of NAC followed by RC, RC as first treatment, trimodal therapy, chemotherapy and/or radiation alone, and no treatment. We then identified factors associated with receiving NAC prior to RC. RESULTS: There was a notable increase in the use of NAC followed by RC over the study period, from 3.68% in 2004 to 14.83% in 2013 (P < 0.001). Factors associated with decreased odds of receiving this regimen included being older, Black, uninsured, less educated, and more burdened by comorbidities. Rates of trimodal therapy and chemotherapy and/or radiation alone remained relatively constant (approximately 5 and 17%, respectively). There was a consistent decline in the proportion of patients who did not receive any treatment, down to 34.20% in 2013. CONCLUSION: Trends in localized MIBC treatment have evolved substantially since the early 2000s, and certain patient characteristics are associated with lower odds of receiving the current standard of care. This serves as a foundation from which to judge the impact of the upcoming immunotherapy era on the treatment landscape for this disease.
Entities:
Keywords:
Bladder cancer; Epidemiology; Health services
Authors: Raymond H Mak; Daniel Hunt; William U Shipley; Jason A Efstathiou; William J Tester; Michael P Hagan; Donald S Kaufman; Niall M Heney; Anthony L Zietman Journal: J Clin Oncol Date: 2014-11-03 Impact factor: 44.544
Authors: Alexander P Cole; Maxine Sun; Stuart R Lipsitz; Akshay Sood; Adam S Kibel; Quoc-Dien Trinh Journal: Cancer Date: 2018-02-06 Impact factor: 6.860
Authors: Atreya Dash; Matthew D Galsky; Andrew J Vickers; Angel M Serio; Theresa M Koppie; Guido Dalbagni; Bernard H Bochner Journal: Cancer Date: 2006-08-01 Impact factor: 6.860
Authors: Jeffrey J Leow; Stephen Reese; Quoc-Dien Trinh; Joaquim Bellmunt; Benjamin I Chung; Adam S Kibel; Steven L Chang Journal: BJU Int Date: 2015-01-26 Impact factor: 5.588
Authors: Joshua E Rosen; Jacquelyn G Hancock; Anthony W Kim; Frank C Detterbeck; Daniel J Boffa Journal: Ann Thorac Surg Date: 2014-10-18 Impact factor: 4.330
Authors: Thomas Seisen; Maxine Sun; Stuart R Lipsitz; Firas Abdollah; Jeffrey J Leow; Mani Menon; Mark A Preston; Lauren C Harshman; Adam S Kibel; Paul L Nguyen; Joaquim Bellmunt; Toni K Choueiri; Quoc-Dien Trinh Journal: Eur Urol Date: 2017-04-12 Impact factor: 20.096
Authors: Sean A Fletcher; Philipp Gild; Alexander P Cole; Malte W Vetterlein; Adam S Kibel; Toni K Choueiri; Guru P Sonpavde; Mark A Preston; Daniel Pucheril; Mani Menon; Maxine Sun; Stuart R Lipsitz; Quoc-Dien Trinh Journal: Urol Oncol Date: 2018-02-15 Impact factor: 3.498
Authors: S Machele Donat; Ahmad Shabsigh; Caroline Savage; Angel M Cronin; Bernard H Bochner; Guido Dalbagni; Harry W Herr; Matthew I Milowsky Journal: Eur Urol Date: 2008-07-14 Impact factor: 20.096
Authors: Nikhil V Kotha; Abhishek Kumar; Tyler J Nelson; Edmund M Qiao; Alex S Qian; Rohith S Voora; Rana R McKay; Brent S Rose; Tyler F Stewart Journal: Urol Oncol Date: 2022-02-23 Impact factor: 2.954
Authors: Nikhil V Kotha; Abhishek Kumar; Tyler J Nelson; Edmund M Qiao; Alex S Qian; Rohith S Voora; Rana R McKay; Tyler F Stewart; Brent S Rose Journal: Adv Radiat Oncol Date: 2021-10-25